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Abstract
Background: Different strains of influenza virus are affecting a large number of people worldwide. Many synthetic
antiviral medicines are available for influenza virus in the market. But still there is a need for the development of
universal drugs against these strains of influenza virus.
Methods: For this purpose conserved residues within the influenza virus nucleoprotein have been retrieved. The
drugs, previously known to have antiviral properties, were screened to identify the best candidate universal drug
against Influenza virus strains. Compounds from leaf extracts of neem, were also screened to identify the natural
drugs without side effects.
Result: Molecular docking identified three potential compounds (Nimbaflavone, Rutin, and Hyperoside) having
perfect binding with reported conserved residues (ASP302, SER50) of influenza virus nucleoprotein that is involved
in the binding of drugs. Further analysis showed Hyperoside as a universal drug against various influenza strains.
Some chemical drugs were also evaluated through screening against nucleoprotein. The results showed six drugs
(OMS, CBX, LGH, Naproxen, BMS-883559, and BMS-885838) which were interacting with same conserved residues
(ASP302, TYR52, SER50, GLY288, SER376, and ARG99) as were found in the case of neem phytochemicals.
Hyperoside from neem leaf extract along with drugs LGH, Naproxen, BMS-885838, and BMS-883559 showed best
interactions with conserved residues of nucleoprotein.
Conclusion: The compound Hyperoside from neem leaf extract along with drugs LGH, Naproxen, BMS-885838, and
BMS-883559 showed best interactions with conserved residues of nucleoprotein. So these compounds have been
identified for their potential against influenza strains to be utilized as a universal drug.
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Background
Influenza is a significant health problem due to its rapid
transmission and high mortality rate. It is a respiratory in-
fection caused by the influenza virus [1] belonging to the
family Orthomyxoviridae. The virus has single stranded
and segmented RNA genome which encodes 8 proteins.
For the propagation of influenza virus, the nucleoprotein
(NP) matrix (M1, M2), neuraminidase (NA), hemagglutinin
(HA) and three viral polymerase subunits (PB1, PB2 and
PA) play an active role [2]. Influenza virus is classified into
three groups and has more than 10 strains. Its genome is
highly variable having high rate of mutation which make it
resistant to many drugs.
Previously the disease was cured by using nucleic acid
protein inhibitors, neuraminidase inhibitors (e.g. Zanamivir,
Oseltamivir), ion channel blockers (e.g. Amantadine,
Rimantadine) and siRNA technique [3]. The whole concept
of the gene regulation and proteome function can be used
to predict projected motifs antiviral drug target of influenza
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A virus [4]. Host specific epitopes of influenza A virus sur-
face proteins NA and HA, have been predicted which could
support in designing the drugs against Influenza virus [5].
Oseltamivir and Zanamivir have been proved as efficient in-
hibitors of NA. Due to the mutation in the active site of
NA and HA, resistance of influenza virus against these
drugs has been reported [6].
Nucleoprotein (NP) is a well-studied highly conserved tri-
meric protein, having a main role in the influenza virus life
cycle. It acts as an RNA single stranded binding protein.
NP is a structural protein of ribonucleoprotein particles
(RNPs). It has a great role in RNPs trafficking between the
nucleus and cytoplasm. NP is also involved in the replica-
tion of RNPs. NP directly binds with M1, PB1 and PB2. In
infection stage, RNPs are being released in the cytoplasm.
Due to the interaction of host proteins with NP the process
of RNPs import in nucleus and export in the cytoplasm
takes place. The sequence of NP only differs 11% in all re-
ported strains, contributing towards its suitability as a tar-
get for universal drug development against all influenza
virus strains [7, 8].
By random screening, Nucleozin is recently discovered
compound, which induces NP aggregation, by inhibiting
viral replication and accumulation of NP in the nucleus.
Successive structure determination of NP bound with an
analog of Nucleozin identified a NP dimer with back-to-
back organization between the monomers, causing an
interface which docks, two anti-parallel ligand molecules
around the two ligand binding sites. Mutations causing re-
sistance against Nucleozin have also been reported [8, 9].
Medicinal plants are very important for treatment of dif-
ferent diseases, mainly in the countries where there are in-
sufficient resources. Uses of traditional medicines are
mainly encouraged in most of the world population [10].
These traditional medicines have least side effects than
other allopathic medicines, one of the major reasons to iso-
late and process these compounds from plants [11]. Neem
is a medicinal plant and has been grown for its universal
importance in recent years. Neem has been extensively
used in Ayurveda, Unani, and Homeopathic medicines. It
has a huge range of chemically and structurally different
biologically active chemicals. More than 140 chemically ac-
tive compounds have been isolated from different parts of
this plant including i.e. flowers, leaves, seeds, roots, fruits,
and bark and are being used traditionally as a cure for
many diseases. These active compounds have been identi-
fied as anti-inflammatory, anti-ulcer, anti-hyperglycaemic,
immune-modulator, anti-mutagenic, anti-carcinogenic,
anti-oxidant, and anti-viral drugs [12].
Neem elements are mainly divided in two groups: Non-
isoprenoids and Isoprenoids. The non-isoprenoids comprise
of proteins, sulphurous compounds, carbohydrates and
polyphenolics including dihydrochalcone, flavonoids, cou-
marin, and aliphatic compounds. The isoprenoids consist of
di-terpenoids and tri-terpenoids which include azadirone,
protomeliacins, limonoids and some derivatives such as
nimbin, vilasinin, salanin and azadirachtin [10]. By an alco-
holic extract of neem leaves a dose dependent substantial
decrease in blood pressure has also been reported [13].
In the background of above debated medications by
neem, this study has been designed to screen active
compounds of neem against the influenza virus nucleo-
protein through molecular docking and to study their
interaction pattern. Moreover, already reported ten
drugs against various influenza virus strain nucleopro-
teins were also used for comparison through molecular
docking and determination of their interaction patterns
with NP conserved residues.
Methods
In-silico analysis of neem leave’s active chemicals against
influenza virus nucleoprotein was carried out. To acquire
this, chemical structures of compounds of neem leaves
were retrieved in MOL format from chemical database
PubChem available on NCBI website. Some of the chem-
ical compounds were drawn in MOL format by using
Chemdraw software. Nucleoprotein structure [PDBID:
3RO5] used for docking purpose was downloaded from
Protein Data Bank (PDB). For molecular docking analysis,
Molecular Operating Environment (MOE) software was
used [14].
Finding the nucleoprotein conserved residues within and
among the influenza strains
In order to find the conserved residues of nucleoprotein
within and among the strains of influenza virus active
against human (H1N1, H1N2, H2N2, H2N3, H5N1,
H7N2, H7N3, H7N7 and H9N2), the available nucleopro-
tein sequences of each strain were retrieved from NCBI
protein database. At first, the retrieved nucleoprotein se-
quences of each strain were aligned by multiple alignment
tool Clustal Omega (http://www.ebi.ac.uk/Tools/msa/
clustalo/) to develop a consensus sequence for each strain
and to identify conserved residues within the strain. The
conserved residues consensus sequences of all the strains
were again aligned using the CLC Genomics Workbench
8 to get the final conserved consensus sequence among
the all strains (Fig. 1).
Molecular docking
Preparation of protein structure (Receptor)
Three-dimensional model of influenza virus Nucleopro-
tein was retrieved from PDB [PDB ID: 3RO5]. All the
water molecules were removed by using MOE software.
After removal of water molecules, hydrogen atoms were
added to the receptor protein. Optimization of receptor
molecule was achieved through energy minimization and
3D protonation by using AMBER99 force field option of
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Fig. 1 (See legend on next page.)
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MOE. The gradient was 0.05 and receptor was minimized
unless root mean square gradient reached below 0.05.
After that the receptor protein was 3D protonated and
then hydrogen molecules were hidden by using hide mol-
ecule option of MOE.
There were three ligand molecules attached to the re-
ceptor molecule because nucleoprotein is a trimeric pro-
tein, so one ligand was attached to one chain of protein.
Two of them were deleted by using sequence bar to get
the single docking site and then pocket of the remaining
ligand was used as the docking site. Surface and maps
option of MOE was used to point out the surface of the
docking site and pocket residues. This energy minimized
and 3D protonated receptor molecules were then used
for docking analysis.
Preparation of ligand structure and construction of
database
The structures of neem leave’s biologically active com-
pounds and reported drugs against influenza virus nucleo-
protein were downloaded from the PubChem database in
2D format. Some structures of chemical compounds were
not presented in the PubChem database so their 2D struc-
tures were retrieved from literature and drawn in 3D for-
mat by using ChemDraw software. For preparation of
ligand structures for docking, hydrogen atoms were added
to each ligand and their energy was minimized by using
the MMFF94X force field at 0.05 gradients. Then these
ligand structures were saved in .mol2 file format.
The two databases (one for neem leaf chemicals and
other for already reported drugs) of ligands were created
separately in MOE software. Ten previously reported drugs
included in the database were: Nucleozin; (+)-(S)-2-(6-












tro-phenyl]pyridine-2-carboxamide [BMS-885838]; and N-
[4-chloranyl-5-[4-[[3-(2-methoxyphenyl)-5-methyl-1,2-oxaz
ol-4-yl]carbonyl]piperazin-1-yl]-2-nitro-phenyl]thiophene-2
-carboxamide [BMS-883559] [7, 15, 16]. These databases
were saved in .mdb format and were further used for dock-
ing against the target receptor protein.
Docking analyses
After preparation of receptor protein and ligand molecules,
molecular docking was executed against the databases
mentioned earlier. Ligands were docked with receptor by
choosing the pocket of already present ligand in the recep-
tor protein by using MOE. There were 20 amino acids in
that pocket; LEU315, SER376, TRP104, LEU56, TYR313,
GLU53, TYR52, SER50, ARG99, GLU294, ALA284,
TYR289, ARG26, ASP302, ARG305, TYR296, ASP290,
ALA284, SER314, and LYS288. Docking output database
files containing receptor ligand complex were saved in
.mdb format. The docked complexes were sorted with re-
spect to increasing S value (the final score to indicate bind-
ing free energy). The complexes with minimum S values
were taken to evaluate the interactions of ligands with the
active site residues of the receptor protein. The best hydro-
gen bonding and π-π interactions were analyzed by the ligX
option of MOE.
Results
Finding conserved residues within and among influenza
virus nucleoprotein
To find the conserved residues in all the strains of influ-
enza virus (Fig. 1), alignment was done by using Clustal
Omega and CLC Genomics Workbench 8 as described
earlier. In the Fig. 1 conservation of residues is shown by
vertical bars. The alignment showed that nucleoprotein is
a highly conserved protein (81.73%).
Docking analyses against neem leaf chemicals
Docking of influenza virus nucleoprotein against neem
leaf chemicals resulted in 3 complex conformations. Nim-
baflavone showed least S-score and interacted with the
ARG305, TYR289, TYR52, and ASP302 residues of nu-
cleoprotein (Table 1; Fig. 2: 1A & 1B). The other two com-
pounds (Rutin and Hyperoside) were also having a lower
S-score and strong hydrogen bonds with multiple residues
of the nucleoprotein (Table 1, Fig. 2: 2A-3B). All these
compounds showed interactions with TYR289 residue of
the selected pocket of nucleoprotein.
ARG305 residue showed interaction with Nimbaflavone
and Rutin, while TYR52 showed the interactions with Nim-
baflavone and Hyperoside. ASP302 showed interaction with
(See figure on previous page.)
Fig. 1 Multiple sequence alignment of influenza virus nucleoprotein consensus sequences of each strain (i.e. H5N1, H7N2, H7N3, H9N2, H7N7,
H1N1, H2N3, H1N2 and H2N2) using CLC Genomics Workbench 8. For the development of each consensus sequence, all the available
nucleoprotein sequences of above said strains were retrieved from NCBI database and were converted to consensus sequences using CLC
Genomics Workbench 8. The colored bars at the bottom are representing the conservation %age
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both Nimbaflavone and Rutin while SER50 as well as
GLY288 interacted with Rutin only.
Docking analysis against reported drugs
Docking of influenza virus nucleoprotein against previously
reported drugs resulted in six complex conformations
(Table 2; Fig. 3). These drugs were also selected on the basis
of low S-value and the interaction with the nucleoprotein
residues. The interactions were shown in Fig. 3. The OMS,
CBX and LGH showed interactions with (ARG305,
ASN309), (ARG305, ASN309) and (TYR52, GLY288) re-
spectively, while naproxen with ARG99, TYR52, SER376;
BMS-883559 with ASN309, TYR52 and BMS-885838 with
SER50, SER376, respectively.
Discussion
Nucleoprotein (NP) is reported to have a main role in the
life cycle of influenza virus. It acts as a single stranded RNA
binding protein that plays a significant role in ribonucleo-
protein particles (RNPs) trafficking between the nucleus
and cytoplasm. It is structural protein of RNPs that is in-
volved in their replication. Consensus sequences taken from
aligning all the sequences of each influenza strains, separ-
ately, were used for the further alignment. The results of
the consensus sequence’s further alignment showed that
NP is near about 81.78% conserved in all the influenza
strains. These results were in accordance with Portela and
Digard [8], who reported that NP only differs 11% in all re-
ported strains. These reasons are contributing towards its
suitability as a target for universal drug development
against all influenza virus strains [7, 8].
For docking purpose the receptor and ligands were pre-
pared and docked as described by Ahad et al., [17]. The
docking showed that ARG305, TYR289, TYR52, ASP302,
SER50, GLY288, and ASN309 were the residues involved
in the interaction with the neem leaf extract chemicals
(Table 1). These results are in accordance with the findings
of Cianci et al., [18] who also reported the interaction of
Aryl piperazine amides inhibitor with TYR52, TYR289, and
ASN309 pocket residues. ASP302, GLY288 and ASN309
Table 1 Docking score (S) and interaction sites of neem

















−28.3207 ASN309, TYR289, TYR52
Fig. 2 Interaction diagrams of phytochemicals from Neem leaf extract compounds with influenza virus nucleoprotein. Where; 1A & 1B are two
dimensional and three dimensional interaction diagrams of ARG305, TYR289, TYR52 and ASP302 residues of influenza virus nucleoprotein with
Nimbaflavone, respectively; 2A & 2B are showing the interaction of ARG305, TYR289, ASP302, SER50 and GLY288 residues of nucleoprotein with
Rutin; and 3A & 3B are illustrating the interaction of ASN309, TYR289 and TYR52 residues with Hyperoside. Interaction diagrams were attained by
using ligand interaction analysis feature of MOE
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Table 2 Docking score (S) and interaction sites of reported drugs against influenza virus nucleoprotein























Fig. 3 Interaction diagrams of reported drugs with influenza virus nucleoprotein. Whereas; 1A & 1B are showing binding of OMS with ARG305,
ASN309; 2A & 2B are illustrating CBX interactions with ARG305, ASN309; 3A & 3B are showing interactions of LGH with TYR52, GLY288 residues of
nucleoprotein, respectively. Furthermore, 4A & 4B are describing naproxen interactions with ARG99, TYR52, SER376 residues; While 5A & 5B of BMS-
883559; 6A of BMS-885838; and 6B of BMS-885838, respectively. Interaction diagrams were attained by using ligand interaction analysis feature of MOE
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were found to be conserved residues in the nucleoprotein
of influenza virus strains. However in H7N7 influenza
strain, TYR50 and TYR52 were substituted with ASN50
and HIS52, respectively, while in H2N3 strain TYR289 was
amended with HIS289. ARG305 was common among
H5N1, H7N2, H7N3, H9N2 and H1N1 strains, but
substituted with LYS305 in H7N7, H2N3, H1N2 and
H2N2 strains (Fig. 1).
Out of investigated neem leaf chemicals, Hyperoside have
not shown any interaction with ARG305 as compared to
other two drugs. Furthermore, TYR289 and TYR52 inter-
acting residues were not present in H2N3 and H7N7, re-
spectively. These observations suggested that Hyperoside
can be used as antiviral drug against entire influenza virus
strains except H2N3 and H7N7. Literature also depicts that
Hyperoside and Nimbaflavone have antiviral activities,
while Rutin has antiviral, antifungal and antimicrobial activ-
ities [19]. Hyperoside is also reported to be considerably ef-
fective against hepatitis B virus (HBV) [20, 21].
The previously reported drugs OMS, CBX and LGH
showed interactions with (ARG305, ASN309), (ARG305,
ASN309) and (TYR52, GLY288), respectively, while na-
proxen showed with ARG99, TYR52, SER376; BMS-
883559 with ASN309, TYR52 and BMS-885838 with
SER50, SER376, respectively. These results were also in
accordance with Lejal, et al., [22], who have reported the
interaction of naproxen with NP of influenza virus.
The docking of nucleoprotein with already reported
drugs has shown that SER50, TYR52, ARG99, GLY288,
ARG305, ASN309, and SER376 residues of nucleoprotein
were involved in interaction. Out of these, ARG99,
GLY288, ASN309, and SER376 residues were found to be
conserved among influenza virus strains (Fig. 1). SER50
and TYR52 were changed in H7N7 strain with ASN50 and
HIS52, respectively. TYR289 has been substituted with
HIS289 in H2N3 influenza strain. ARG305 was found to be
common among H5N1, H7N2, H7N3, H9N2, and H1N1
strains, but substituted with LYS305 in H7N7, H2N3,
H1N2 and H2N2 strains as mentioned before. So from
Table 2, it is concluded that drugs LGH, Naproxen, BMS-
885838 and BMS-883559 interacted with conserved resi-
dues, so they can be used as universal drugs against influ-
enza virus strains except H7N7 because one of its
interacting residue is missing. This evaluation corresponds
with Davis et al., [23] who proposed that 289 and 309 resi-
dues of nucleoprotein are involved in the binding of the
drugs with nucleoprotein.
There is a hypothesis that increasing concentration of
nucleoprotein is a switch for replication and transcription
of the genome. Due to this reason there is a need to find a
drug effective against conserved regions of the influenza
virus proteins involved in replication process such as nu-
cleoprotein. The outcome of the current study will be
helpful to identify the universal drug against all strains of
influenza virus; to find out conserved residues within and
among influenza virus nucleoprotein as a target for drug
discovery [24].
Conclusion
Due to strain variations among influenza virus, it is the
need of the time to identify the conserved residues among
different strains as a target for universal drug discovery
based on compounds extracted from natural sources like
the neem leaves. In the present study, nucleoprotein was
selected and screened against compounds extracted from
neem leaves using in-silico screening and molecular dock-
ing simulation techniques. The compound Hyperoside
from neem leaf extract along with drugs LGH, Naproxen,
BMS-885838 and BMS-883559 showed best interactions
with conserved residues of the nucleoprotein. So these
compounds have been identified for holding great potential
for utilization as a universal drug against influenza
strains. These observations require further considerations








triazole-4-carboxamide; HA: Hemagglutinin; LGH: 4-(2-chloro-4-
nitrophenyl)piperazin-1-yl][3-(2-methoxyphenyl)-5-methyl-1,2-oxazol-4-
yl]methanone; M: Matrix; NA: Neuraminidase; Naproxen: (+)-(S)-2-(6-





The authors are grateful for the contributions of the members of the Protein
Engineering Section, Bioprocess Engineering Lab, Department of
Bioinformatics and Biotechnology, Government College University (GCUF),
Faisalabad and Plant Biotechnology Lab, Centre of Excellence in Molecular
Biology (CEMB), University of the Punjab, Lahore, Pakistan.
Funding
The study is not funded by any funding body.
Availability of data and materials
Accession numbers and their databases have been mentioned in the
manuscript.
Authors’ contributions
The study execution and manuscript drafting was carried out by AA. The
data analysis and manuscript revision was done by MRJ. The study planning
and manuscript revision was done by AQR. Proof reading of the manuscript
and its grammatical correction was carried out by TH. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not Applicable.
Ethics approval and consent to participate
Not Applicable.
Ahmad et al. BMC Complementary and Alternative Medicine  (2016) 16:519 Page 7 of 8
Received: 21 July 2016 Accepted: 19 November 2016
References
1. Boyd M, Clezy K, Lindley R, Pearce R. Pandemic influenza: clinical issues.
Med J Aust. 2006;185(10):S44.
2. Kamal RP, Tosh C, Pattnaik B, Behera P, Nagarajan S, Gounalan S, et al.
Analysis of the PB2 gene reveals that Indian H5N1 influenza virus belongs
to a mixed-migratory bird sub-lineage possessing the amino acid lysine at
position 627 of the PB2 protein. Arch Virol. 2007;152(9):1637–44.
3. Stiver G. The treatment of influenza with antiviral drugs. Can Med Assoc J.
2003;168(1):49–57.
4. Somvanshi P, Singh V, Seth P. Phylogenetic and computational proteome
analysis of Influenza A virus subtype H5N1. Internet J Genomics Proteomics.
2008;3:2.
5. Somvanshi P, Singh V, Seth P. Prediction of epitopes in hemagglutinin and
neuraminidase proteins of influenza A virus H5N1 strain: A clue for
diagnostic and vaccine development. OMICS. 2008;12(1):61–9.
6. Smit M, Beynon KA, Murdochm DR, Jennings LC. Comparison of the NOW
Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A+ B assays,
and immunofluorescence with viral culture for the detection of influenza A
and B viruses. Diagn Microbiol Infect Dis. 2007;57(1):67–70.
7. Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, Discotto L, et al.
Inhibition of influenza virus replication via small molecules that induce the
formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci.
2011;108(37):15366–71.
8. Portela A, Digard P. The influenza virus nucleoprotein: a multifunctional RNA-
binding protein pivotal to virus replication. J Gen Virol. 2002;83(4):723–34.
9. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, et al. Identification of influenza
A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600–5.
10. Jalil A, Ashfaq UA, Shahzadi S, Javed MR, Rasul I, Rehman SU, et al.
Screening and design of anti-diabetic compounds sourced from the leaves
of neem (Azadirachta indica). Bioinformation. 2013;9(20):1031.
11. Akanksha, Srivastava AK, Maurya R. Antihyperglycemic activity of compounds
isolated from Indian medicinal plants. Indian J Exp Biol. 2010;48(3):294–8.
12. Subapriya R, Nagini S. Medicinal properties of neem leaves: a review. Curr
Med Chem Anti Cancer Agents. 2005;5(2):149–56.
13. Koley K, Lal J. Pharmacological effects of Azadirachta indica (neem) leaf
extract on the ECG and blood pressure of rat. Indian J Physiol Pharmacol.
1994;38(3):223–5.
14. Khan M, Qasim M, Ashfaq UA, Idrees S, Shah M. Computer aided screening of
Accacia nilotica phytochemicals against HCV NS3/4a. Bioinformation. 2013;9(14):710.
15. Cheng H, Wan J, Lin MI, Liu Y, Lu X, Liu J, et al. Design, Synthesis, and in
Vitro Biological Evaluation of 1H-1, 2, 3-Triazole-4-carboxamide Derivatives
as New Anti-influenza A Agents Targeting Virus Nucleoprotein. J Med
Chem. 2012;55(5):2144–53.
16. Shen Z, Lou K, Wang W. New small-molecule drug design strategies for
fighting resistant influenza A. Acta Pharm Sin B. 2015;5(5):419–30.
17. Ahad A, Ahmad A, Din SU, Rao AQ, Shahid AA, Husnain T. In silico study for
diversing the molecular pathway of pigment formation: an alternative to
manual coloring in cotton fibers. Front Plant Sci. 2015;6:751.
18. Cianci C, Gerritz SW, Deminie C, Krystal M. Influenza nucleoprotein: promising
target for antiviral chemotherapy. Antiviral Chem Chemother. 2013;23(3):77–91.
19. Orhan DD, Özçelik B, Özgen S, Ergun F. Antibacterial, antifungal, and
antiviral activities of some flavonoids. Microbiol Res. 2010;165(6):496–504.
20. Wu LL, Yang XB, Huang ZM, Liu HZ, Wu GX. In vivo and in vitro antiviral
activity of hyperoside extracted from Abelmoschus manihot (L) medik. Acta
Pharmacol Sin. 2007;28:3.
21. Gangar SC, Sandhir R, Koul A. Anti-clastogenic activity of Azadirachta indica
against benzo (a) pyrene in murine forestomach tumorigenesis bioassay.
Acta Pol Pharm. 2010;67:381–90.
22. Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, et al. Structure-
based discovery of the novel antiviral properties of naproxen against the
nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57(5):
2231–42.
23. Davis AM, Chabolla BJ, Newcomb LL. Emerging antiviral resistant strains of
influenza A and the potential therapeutic targets within the viral
ribonucleoprotein (vRNP) complex. Virol J. 2014;11(1):1.
24. Mullin AE, Dalton RM, Amorim MJ, Elton D, Digard P. Increased amounts of
the influenza virus nucleoprotein do not promote higher levels of viral
genome replication. J Gen Virol. 2004;85(12):3689–98.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ahmad et al. BMC Complementary and Alternative Medicine  (2016) 16:519 Page 8 of 8
